Oxidative stress and asymmetric dimethylarginine are associated with cardiovascular complications in hemodialysis patients: Improvements by L-arginine intake

Kidney and Blood Pressure Research

Volumn 31, Issue 3, 2008, Pages 189-195

  El Mesallamy, Hala O ^a   Abdel Hamid, Sherehan G ^a   Gad, Mohamed Z ^a,b  

^a Ain Shams University   (Egypt)

^b German University in Cairo   (Egypt)

Author keywords

Asymmetric dimethylarginine; Chronic kidney disease; Hemodialysis; Homocysteine; L Arginine; Oxidative stress

Indexed keywords

ARGININE; HOMOCYSTEINE; MALONALDEHYDE; MYELOPEROXIDASE; N(G),N(G) DIMETHYLARGININE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; ARGININE; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PEROXIDASE; RENAL DIALYSIS; RISK FACTORS;

EID: 46249107339     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000135655     Document Type: Article

References (33)

1. Cross J: Endothelial dysfunction in uraemia. Blood Purif 2002;20:459-461.
2. Pawlak K, Pawlak D, Mysliwiec M: Serum matrix metalloproteinase-2 and increased oxidative stress are associated with carotid atherosclerosis in hemodialyzed patients. Atherosclerosis 2007;190:199-204.
3. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-2678.
4. Kielstein JT, Frolich JC, Haller H, Fliser D: ADMA (asymmetric dimethylarginine); an atherosclerotic disease mediating agent in patients with renal disease. Nephrol Dial Transplant 2001;16:1742-1745.
5. Vallance P, Leon A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;399:572-575.
6. Zoccali C, Mallamaci F, Tripepi G: Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol 2004;15:S77-S80.
7. Cherla G, Jaimes EA: Role of L-arginine in the pathogenesis and treatment of renal disease. J Nutr 2004;134:2801S-2806S.
8. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE: Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-709.
9. Faraci FM: Hyperhomocysteinemia: a million ways to lose control. Arterioscler Thromb Vasc Biol 2003;23:371-373.
10. Galle J: Oxidative stress in chronic renal failure. Nephrol Dial Transplant 2001;16:2135-2137.
11. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T, Simoons ML, Hamm CW: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440-1445.
12. Maruyama Y, Lindholm B, Stenvinkel P: Inflammation and oxidative stress in ESRD: the role of myeloperoxidase. J Nephrol 2004; 17:72-76.
13. Watanabe G, Tomiyama H, Doba N: Effects of oral administration of L-arginine on renal function in patients with heart failure. J Hypertens 2000;18:229-234.
14. Friedewald WT, Levy RT, Friedrickson DS: Estimation of the concentration of the low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
15. Uchiyama M, Mihara M: Determination of malondialdehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1978; 86:271-278.
16. Manktelow A, Meyer AA: Lack of correlation between decreased chemotaxis and susceptibility to infection in burned rats. J Trauma 1986;26:143-148.
17. Grisham MB, Benoit JN, Granger DN: Assessment of leukocyte involvement during ischemia and reperfusion of intestine. Methods Enzymol 1990;186:729-742.
18. Schulze F, Wesemann R, Schwedhelm E, et al: Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004;42:1377-1383.
19. Vaziri ND, Ni Z, Oveisi F, Liang K, Pandian R: Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 2002; 39:135-141.
20. Kaysen GA, Eiserich JP: The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 2004;15: 538-548.
21. Stenvinkel P, Pecoits-Filho R, Lindholm B: Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 2003;14:1927-1939.
22. Zhang R, Brennan M, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001;286:2136-2142.
23. Zhang R, Brennan ML, Shen Z, MacPherson JC, Schmitt D, Molenda CE, Hazen SL: Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem 2002; 277:46116-46122.
24. Vallance P, Leiper J: Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004;24:1023-1030.
25. Fliser D, Kielstein JT, Haller H, Bode-Böger SM: Asymmetric dimethylarginine: a cardiovascular risk factor in renal disease? Kidney Int Suppl 2003;63:S37-S40.
26. Cooke JP: Asymmetrical dimethylarginine: the uber marker. Circulation 2004;109:1813-1819.
27. Stuhinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, J Cooke JP: Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001;104:2569-2575.
28. Böger RH, Bode-Böger SM, Sydow K, Heistad DD: Lentz SR: Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000;20:1557-1564.
29. Lin WT, Yang SC, Chen KT, Huang CC, Lee NY: Protective effects of L-arginine on pulmonary oxidative stress and anti-oxidant defenses during exhaustive exercise in rats. Acta Pharmacol Sin 2005;26:992-999.
30. Sydow K, Schwedhelm E, Arakawa N, Bode-Boger SM, Tsikas D, Hornig B, Frolich JC, Boger RH: ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res 2003; 57:244-252.
31. Tome L, Yu L, de Castro I, Campos S, Seguro A: Beneficial and harmful effects of L-arginine on renal ischaemia. Nephrol Dial Transplant 1999;14:1139-1145.
32. Sanders PW: L-Arginine and arginine analogs in progressive renal failure. Blood Purif 1995;13:219-227.
33. Wakabayashi Y, Kikawada R: Effect of L-arginine on myoglobin-induced acute renal failure in the rabbit. Renal Physiol 1996;270: 784-789.